Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Basel, 05 December - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA)...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} WISeKey and Saudi Advanced...
-
New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years ...
-
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} WISeKey to Present at the Imperial...
-
Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective...
-
The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative...
-
MCH Group updates its forecast for 2018 The MCH Group has updated its projection for the 2018 financial result. It expects a negative result prior to special measures of at least CHF 14 million....
-
MCH Group actualise ses prévisions pour 2018 MCH Group actualise son estimation du résultat d’exploitation 2018: le groupe s’attend à un résultat avant mesures exceptionnelles négatif d’au...
-
MCH Group aktualisiert Prognose für 2018 Die MCH Group aktualisiert ihre Hochschätzung des Geschäftsergebnisses 2018: Sie erwartet ein negatives Ergebnis vor Sondermassnahmen von mindestens CHF...
-
Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II...